Enovis Corporation (NYSE:ENOV) Receives Average Rating of “Moderate Buy” from Analysts

Enovis Corporation (NYSE:ENOV) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $44.50.

A number of analysts have weighed in on the company. William Blair assumed coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Needham & Company LLC increased their price objective on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company reduced their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th.

Institutional Trading of Enovis

Several hedge funds have recently made changes to their positions in ENOV. Rubric Capital Management LP acquired a new stake in shares of Enovis in the 3rd quarter valued at approximately $83,435,000. Paradigm Capital Management Inc. NY lifted its holdings in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after buying an additional 732,917 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after buying an additional 434,646 shares during the period. Front Street Capital Management Inc. lifted its holdings in shares of Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after buying an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP lifted its holdings in shares of Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after buying an additional 342,556 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 1.9%

Shares of NYSE:ENOV opened at $21.53 on Thursday. The stock has a market cap of $1.24 billion, a P/E ratio of -1.08 and a beta of 1.38. The firm has a fifty day moving average price of $24.00 and a 200 day moving average price of $24.85. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. Enovis has a 1-year low of $20.82 and a 1-year high of $36.82.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter in the prior year, the business earned $0.81 EPS. Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts predict that Enovis will post 3.65 EPS for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.